[May 27] Spera Pharma to Host Webinar on "Basics of Microbiological Testing in Pharmaceutical QA and Latest CCIT Trends"

Spera Pharma (Headquarters: Osaka, Japan; President: Keitaro Iwaki) will host a webinar on May 27, 2026, titled "Basics of Microbiological Testing in Pharmaceutical QA and Latest CCIT Trends."

About This Webinar

This webinar provides an overview of microbiological testing in pharmaceutical quality assurance, ranging from fundamental principles to the latest trends in Container Closure Integrity Testing (CCIT), an area of increasing importance. The session will organize the objectives and differences between microbial limit tests, sterility tests, and endotoxin tests, emphasizing the significance of suitability testing and reaction interference testing, along with practical considerations. The second half of the session will cover quantitative CCIT and microbial challenge testing based on regulatory trends, as well as the testing capabilities and equipment features available at Spera Pharma.

Recommended for: - Researchers struggling to determine the scope of testing methods and condition settings for microbial limit tests, sterility tests, and endotoxin tests. - Researchers who understand pharmacopeial requirements for suitability testing and reaction interference testing but are uncertain about practical implementation. - Researchers looking to organize their approach to microbiological testing based on sample characteristics. - Researchers wanting to understand the roles and integration of sterility evaluation via microbiological testing and CCIT. - Researchers considering at what stage and which testing methods to consult or outsource to external experts based on the development phase.

Event Overview

Title: Basics of Microbiological Testing in Pharmaceutical QA and Latest CCIT Trends Date and Time: Wednesday, May 27, 2026, 13:30–14:15 Format: Online (Microsoft Teams Webinar) Participation Fee: Free Registration: Please apply via the registration button below.

* This webinar is primarily intended for professionals in pharmaceutical companies and research institutions. Due to the nature of the content, participants from direct competitors may be declined. * Program contents are subject to change without notice.

Speaker Profile

Koichi Honjo Spera Pharma Associate Director, Development & Analytical Research Laboratories, Osaka Research Center

After completing his Master's degree at Kyoto University Graduate School of Energy Science in 2003, Koichi Honjo joined Shimadzu Corporation, where he worked on contract services for gene and proteome analysis. In 2006, he moved to Chlorella Light Co., Ltd., where he was in charge of developing lactic acid bacteria beverages. In 2009, he joined Falco Biosystems Ltd., where he was involved in food and environmental microbial testing, as well as microbiological work related to pharmaceutical raw materials and regenerative medicine products. Since 2020, he has been with Spera Pharma, where he serves as a specialist in the microbiology field, providing technical support and handling pharmaceutical-related microbiological work.